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lated into patients experiencing 37% higher average pain intensity, an 8% decrease 
in QoL, and total additional costs of ~$1277 annually. This study provided a concep-
tual framework to model the health-economic impact of dosing variations based on 
actual dosing information in a realistic and intuitive way. This novel concept can also 
be applied to other disease areas to assess pharmaco-economic outcomes.
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OBJECTIVES: Medications, regardless of effectiveness, do not work in patients who 
do not take them. Poor adherence to prescribed medication regimens has been a well-
recognized problem in all of medicine and patients with chronic conditions, such as 
depression, are less likely to follow prescription orders than those with acute condi-
tions. In depression, several studies have reported a medication adherence rate of 
about 72% within the ﬁ rst month of treatment which drops sharply to about 43% 
after 6 months of treatment. Pharmacists may be able to help improve adherence rates, 
yet no single review has examined the impact of pharmacist interventions on adherence 
to antidepressants. The aim of this study was to summarize the literature and deter-
mine whether pharmacist intervention will 1) improve adherence in depression; and 
2) improve patient-reported outcomes (PRO). METHODS: A systematic review of the 
literature was conducted using the PubMed database to retrieve studies examining the 
impact of pharmacist interventions on adherence to antidepressants and on patient-
reported outcomes, from 1990 to 2010. The following MESH terms were used: 
pharmacist intervention, medication intervention, depression, medication adherence, 
health-related quality of life, patient reported outcomes, and antidepressants. a total 
of 25 papers were retrieved with 11 excluded on the basis of abstract or full-text 
review resulting in 14 studies suitable for inclusion. RESULTS: The most common 
intervention strategy that pharmacists utilized was a combination of drug monitoring 
(baseline assessment and treatment follow-up), drug counseling by telephone and 
personal interviews, and patient education (about medication side effects).The results 
of these interventions were positive, improvement varying from 15% to 19%, and 
also, HRQL improved to varying degrees. CONCLUSIONS: The studies support the 
roles of pharmacists in providing interventions to improve medication adherence in 
depression. The results can provide a basis for future studies examining the cost-
effectiveness of pharmacist interventions in depression. 
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OBJECTIVES: To analyze the cost-effectiveness, multinomial expected value of perfect 
information (mEVPI), and budget impact of certolizumab pegol (CZP) compared to 
the used ﬁ rst-line subcutaneously administered tumor necrosis factor (TNF) − inhibi-
tors + methotrexate (MTX) and MTX alone in the treatment of moderate-to-severe 
rheumatoid arthritis (RA) in the Finnish setting. METHODS: An Excel-based, proba-
bilistic lifetime Markov cohort model was developed to assess the cost-effectiveness 
and mEVPI. Treatment efﬁ cacy was measured using the ACR-responses (no ACR20, 
ACR20, ACR50, or ACR70) at 3 months. ACR estimated response rates were based 
on adjusted indirect comparison (MTX as the common comparator) of published 
clinical trials. The health state utilities were estimated from the CZP-trials using 
regression models. The inpatient days were linked to patients’ HAQ-scores according 
to published literature. Cost estimates from Finnish sources were used and assessed 
from payer perspective. Cost and health outcomes were discounted with annual 3% 
discount rate. Undiscounted budget impact of CZP was estimated for years 2010–
2013 using Excel model. Equal inpatient costs and treatment efﬁ cacies were assumed 
for all TNF inhibitors. RESULTS: The lifetime costs for CZP + MTX, etanercept + 
MTX, and MTX alone were c179,986, c201,781, and c186,986, respectively. The 
corresponding QALYs (life-years) were 7.041 (15.697), 6.838 (15.646), and 6.336 
(15.547). According to the cost-effectiveness acceptability frontier, CZP + MTX was 
the optimal treatment option with 58% to 73% probability of being cost-effective at 
willingness-to-pay values of c0–30,000 per QALY gained. The respective mEVPI was 
c5058–3701 per patient. Based on clinical responses, CZP + MTX dominated also 
adalimumab + MTX with 100–85% probability of cost-effectiveness (c0–30,000 per 
QALY gained; EVPI c0–218 per patient). The introduction of CZP produced annual 
budgetary net savings of c0.17–0.80 million during 2010–2013 in budget impact 
analysis. CONCLUSIONS: This analysis shows that, on average, CZP + MTX domi-
nated the other subcutaneously injected TNF inhibitors considered or MTX alone in 
the Finish setting. The use of CZP resulted in budgetary net savings.
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OBJECTIVES: To conduct a Discrete Choice Experiment (DCE) to elicit rheumatoid 
arthritis (RA) patients’ preferences regarding treatment with BIOLOGIC AGENTS 
(BA). METHODS: We designed a DCE with RA patients and seven treatment attri-
butes: effectiveness, route of administration, frequency of administration, local and 
systemic adverse effects, severe infections, and out-of-pocket costs. RA patients who 
had never received BA from one private and one public hospital in Buenos Aires were 
included. a multinomial probit regression model (MNP) was used. RESULTS: A total 
of 240 RA participated (mean age 56.2 [SD 13.5], 87% women, median disease dura-
tion 9 years), all receiving conventional DMARDs (84.5% Metotrexate); median 
Clinical Disease Activity Index 7.5, and median HAQ 0.5. All the attributes showed 
to be signiﬁ cant factors affecting choice of treatment. Most attributes levels showed 
coefﬁ cients with the expected signs and were statistically signiﬁcant. Attributes impor-
tance ranking was in the following order: cost, systemic adverse events, frequency of 
administration, efﬁ cacy, route of administration, local adverse events, and serious 
infection (table). Patients had relatively high monthly WTP for treatments that signiﬁ -
cantly reduced the risk of systemic adverse events: mean 331 (95% CI: 212–499) US 
dollars ($) for a reduction from 30% to 10%; of decreasing dose frequency: mean 
$302 (95% CI: 183–461) for going from weekly to monthly administration; increasing 
treatment efﬁ cacy: mean: $386 (95% CI: 285–532) for 40 versus 20 mm reduction in 
patient global assessment VAS), and also for switching from an intravenous to an oral 
therapy: mean $262 (95% CI: 262–555). CONCLUSIONS: Different treatment attri-
butes had a signiﬁ cant and different inﬂ uence in RA patients’ choice of BA. The results 
of the DCE indicated that most respondents would be willing to pay for treatments 
that importantly reduced the risk of systemic adverse effects, dose frequency, with 
increased treatment efﬁ cacy, and with an oral route of administration.
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OBJECTIVES: Studies of orphan drugs are, by nature, confronted with small patient 
populations, meaning that randomized controlled trials (RCTs) will have limited 
statistical power. Enzyme replacement therapy (ERT) is an orphan drug for Pompe 
disease, a metabolic orphan disease, with a prevalence in the The Netherlands of 1 
per 40,000 births. In order to estimate the (cost-)effectiveness of ERT, we developed 
a disease model founded on all available clinical knowledge. METHODS: We devel-
oped a disease model with a strong clinical basis which linked disease-related factors 
with quality-adjusted life-years. The structure of the Wilson-Cleary health outcomes 
model was used as a blueprint. Based on literature and expert opinion, clinically 
relevant aspects of Pompe disease were applied to the distinct entities of the Wilson-
Cleary model. Data from a Dutch cohort study (n = 94, mean follow-up = 2.7 years) 
were used to quantify the relationships between the different entities by means of 
regression analyses. RESULTS: A conceptual model for Pompe disease was developed 
by establishing a clinically plausible pathway from enzyme activity (“biological vari-
ables” in Wilson-Cleary model) via muscle strength and respiratory function 
(“symptom status”), and MCS and PCS from the SF-36 (“functional status”) to the 
ﬁ nal entity of health utility (“quality of life” using EQ-5D and SF-6D). The strengths 
of the relationships between these entities were based on the results of the regression 
analyses. Patient characteristics such as age, gender, and disease duration affected all 
entities in the model. Therapy was assumed to affect only enzyme activity in the model; 
all other health outcomes could only be affected via an impact on enzyme activity. 
CONCLUSION: We have developed a clinically based model to assess the long-term 
cost-effectiveness of ERT in Pompe disease. The approach used here is expected to be 
applicable in the assessment of other orphan drugs.
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OBJECTIVES: Owing to rapid, persistent efﬁ cacy in reducing pain and preventing 
structural damage, tumor necrosis factor-alpha inhibitors (anti-TNFs) has revolution-
ized the treatment of ankylosing spondylitis (AS). However, the high price of anti-
TNFs has limited their use. Recent studies suggest that increased medication costs by 
adopting anti-TNFs may be offset by decreased values of other cost categories. In most 
cost-effectiveness studies on AS treatments, costs were estimated as a whole. Our 
